Janux Therapeutics (JANX) EBIT (2020 - 2026)
Janux Therapeutics (JANX) reported EBIT of -$34.2 million for Q1 2026, up 1.96% year-over-year from -$33.6 million in Q1 2025, and up 19.31% on a QoQ basis from -$42.4 million in Q4 2025.
Janux Therapeutics (JANX) has 7 years of EBIT data on file, last reported at -$34.2 million in Q1 2026.
- Quarterly EBIT rose 1.96% year-over-year to -$34.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$157.0 million (down 38.21% YoY) and the FY2025 annual result came in at -$157.7 million, down 59.51% from the prior year.
- EBIT advanced to -$34.2 million in Q1 2026 per JANX's latest filing, from -$42.4 million in the prior quarter.
- Across five years, EBIT topped out at -$13.5 million in Q1 2022 and bottomed at -$45.1 million in Q2 2025.
- The 5-year median for EBIT is -$20.3 million (2023), against an average of -$25.3 million.
- The widest annual swing landed in 2022, when EBIT sank 492.91%; it then surged 33.38% in 2024.
- Tracing JANX's EBIT over 5 years: stood at -$18.3 million in 2022, then grew by 11.66% to -$16.1 million in 2023, then tumbled by 79.85% to -$29.0 million in 2024, then slumped by 46.1% to -$42.4 million in 2025, then advanced by 19.31% to -$34.2 million in 2026.
- Per Business Quant, the three latest JANX EBIT figures stand at -$34.2 million (Q1 2026), -$42.4 million (Q4 2025), and -$35.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Janux Therapeutics | 914.29 Mn | 914.29 Mn | - | -34.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.21 Mn |
| Dec 31, 2025 | -42.40 Mn |
| Sep 30, 2025 | -35.25 Mn |
| Jun 30, 2025 | -45.12 Mn |
| Mar 31, 2025 | -34.90 Mn |
| Dec 31, 2024 | -29.02 Mn |
| Sep 30, 2024 | -35.84 Mn |
| Jun 30, 2024 | -13.82 Mn |
| Mar 31, 2024 | -20.16 Mn |
| Dec 31, 2023 | -16.14 Mn |
| Sep 30, 2023 | -15.81 Mn |
| Jun 30, 2023 | -20.75 Mn |
| Mar 31, 2023 | -20.28 Mn |
| Dec 31, 2022 | -18.27 Mn |
| Sep 30, 2022 | -18.02 Mn |
| Jun 30, 2022 | -17.26 Mn |
| Mar 31, 2022 | -13.54 Mn |
| Dec 31, 2021 | -13.49 Mn |
| Sep 30, 2021 | -10.90 Mn |
| Jun 30, 2021 | -6.25 Mn |
| Mar 31, 2021 | -2.28 Mn |
| Dec 31, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.26 Mn |
| Jun 30, 2020 | -1.11 Mn |